1 Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
2 CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas), Spain.
3 Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver).
4 Service d’Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, DHU Unity, Pôle des Maladies de l’Appareil Digestif, Hôpital Beaujon, AP-HP, Clichy, France.
Received 7 February 2023.
Accepted 20 February 2023.
J.C.G.-P. reports conflicts of interest with W.L. Gore and Associates, Cook Medical, Shionogi, and Vifor Pharma; grants from Conatus Pharmaceuticals and Theravance Biopharma; and grants from Novartis and Exalenz Bioscience, outside the submitted work. F.T. reports conflicts of interest with W.L. Gore and Associates, outside the submitted work. The other authors declare no conflicts of interest.
All authors drafted and approved the final article.
Correspondence: Juan Carlos García-Pagán, MD, PhD, Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain. ([email protected]).